Received Aug 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 3 | 343DD | — |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | LN75D | — |
Extra Dose Administered; Extra Dose Administered; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 16-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number 343DD, expiry date 30-SEP-2025) for prophylaxis. Co-suspect products included Men ACWY-CRM NVS (Menveo) (batch number LN75D) for prophylaxis. Previously administered products included Meningococcal vaccine A/C/Y/W (1st dose received on 23rd July 2021, batch number U6951AA). On 17-JUL-2025, the patient received the 3rd dose of Menveo. On 20-SEP-2024, the patient received the 2nd dose of Menveo. On 20-SEP-2024, not applicable after receiving Menveo and an unknown time after receiving Menveo, the patient experienced extra dose administered (Verbatim: Extra Dose Administered). On 17-JUL-2025, the patient experienced extra dose administered (Verbatim: Extra Dose Administered). The outcome of the extra dose administered and extra dose administered were not applicable. Additional Information: GSK Receipt Date: 25-JUL-2025 It was reported that a patient who received a third dose of Menveo which led to Extra dose administered. The reporter wanted to confirm if there was any other contraindication. HCP states she was unsure if it was Menactra. She only knew it was a meningococcal ACWY vaccine.